Viridian Therapeutics, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|
| Revenue | $4.0M | $3.5M | $5.7M | $6.5M | $5.5M |
| Cost of Revenue | — | $2.5M | $2.5M | $3.4M | $2.8M |
| Gross Profit | — | $929.0K | $3.2M | $3.1M | $2.7M |
| Gross Margin | — | 26.7% | 56.7% | 48.1% | 49.4% |
| Operating Expenses | |||||
| Research & Development | $19.6M | $13.7M | $1.0M | $347.0K | $225.0K |
| SG&A Expense | $10.9M | $6.8M | $7.7M | $6.9M | $1.4M |
| Operating Income | $-26.5M | $-17.0M | $-11.2M | $-6.9M | $-197.0K |
| Operating Margin | -662.8% | -488.6% | -196.1% | -105.9% | -3.6% |
| Interest Expense | — | $95.0K | $141.0K | $1.0M | $2.0M |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | — | — | $0 | $0 | — |
| Net Income | $-26.5M | $-17.3M | $-11.3M | $-7.9M | $-2.2M |
| Net Margin | -662.3% | -496.8% | -198.5% | -121.7% | -39.3% |
| EPS (Basic) | $-0.46 | $-9.40 | $-7.01 | $-1.17 | $-4.08 |
| EPS (Diluted) | $-0.46 | $-9.40 | $-7.01 | $-1.17 | $-4.08 |
| Shares Outstanding (Basic) | 67.7M | 2.5M | 2.1M | 11.3M | 0 |
| Shares Outstanding (Diluted) | 67.7M | 2.5M | 2.1M | 11.3M | 0 |
| Dividends Per Share | — | — | — | — | — |